About 32 results found for searched term "DPP-4" (0.09 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M55024 | Recombinant Human DPP4/CD26 (HEK293, C-6His) | Cytokines and Growth Factors |
| Dipeptidyl Peptidase 4; DPP IV; ADCP-2 | ||
| DPP4/CD26 is a signal-anchor for type II membrane protein that belongs to the peptidase S9B family. DPP4/CD26 acts as a positive regulator of T-cell coactivation, by binding at least ADA, CAV1, IGF2R, and PTPRC. It’s binding to CAV1 and CARD11 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. | ||
| M55549 | Recombinant Mouse DPP-4/CD26 Protein (HEK293, N-hFc) | Cytokines and Growth Factors |
| Dipeptidyl Peptidase 4; DPP IV | ||
| Dipeptidyl peptidase-4 (DPP4, CD26) is a serine exopeptidase belonging to the S9B protein family. The enzyme is a type II transmembrane glycoprotein, expressed on the surface of many cell types. It is also present in serum and other body fluids in a truncated form (sCD26/DPPIV). | ||
| M1967 | Sitagliptin phosphate monohydrate | Dipeptidyl Peptidase |
| MK-0431, Januvia | ||
| Sitagliptin phosphate (MK-0431) is a potent inhibitor of dipeptidyl peptidase-4 (DPP-4) with IC50 of 19 nM. | ||
| M2341 | Trelagliptin | Dipeptidyl Peptidase |
| SYR-472 | ||
| Trelagliptin (SYR-472) is a novel once-weekly oral DPP-4 inhibitor for type 2 diabetes. | ||
| M2374 | Alogliptin | Dipeptidyl Peptidase |
| SYR-322 | ||
| Alogliptin is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. | ||
| M2814 | Linagliptin | Dipeptidyl Peptidase |
| BI-1356 | ||
| Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM. | ||
| M3435 | Saxagliptin | Dipeptidyl Peptidase |
| BMS-477118 | ||
| Saxagliptin (BMS-477118) is a potent, selective, reversible, competitive and orally active inhibitor of dipeptidyl peptidase 4 (DPP-4) (Ki = 0.6-1.3 nM). Saxagliptin can be used in type 2 diabetes studies. | ||
| M1333 | Talabostat mesylate | Dipeptidyl Peptidase |
| BXCL701 mesylate; Val-boroPro mesylate; PT100 mesylate | ||
| Talabostat mesylate (Val-boroPro mesylate; PT100 mesylate) is an orally active and nonselective dipeptidyl peptidase IV (DPP-IV) inhibitor (IC50 < 4 nM; Ki = 0.18 nM) and the first clinical inhibitor of fibroblast activation protein (FAP) (IC50 = 560 nM). | ||
| M4333 | Calceolarioside-B | Aldose Reductase |
| Calceolarioside B is a natural product isolated from the Stauntonia hexaphylla leaf. Calceolarioside B showed significant inhibitory activity against aldose reductase (RLAR) in rat lens with IC50 value of 23.99 μM. Calceolarioside B could effectively inhibit DPPH radical scavenging activity with IC50 value of 94.60 μM. | ||
| M4532 | Rhodionin | AChR/AChE |
| Rhodionin was isolated from the roots of Rhodiola crenulata and is a specific non-competitive cytochrome P450 2D6 inhibitor with IC50 of 0.761 μM and Ki of 0.769 μM. Rhodionin effectively inhibited acetylcholinesterase (AChE) in a dose-dependent manner with an IC50 range of 57.50 to 2.43 μg/mL. Rhodionin had effective DPPH radical scavenging activity with IC50 of 19.49 μM. | ||
| M4936 | Omarigliptin | Dipeptidyl Peptidase |
| MK-3102 | ||
| Omarigliptin(MK-3102) is a potent, selective and long-acting DPP-4 inhibitor with IC50 of 1.6 nM; highly selective over all proteases tested (IC50 > 67 _mu_M). | ||
| M5399 | Alogliptin Benzoate | Dipeptidyl Peptidase |
| SYR-322 | ||
| Alogliptin is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. | ||
| M5417 | Anagliptin | Dipeptidyl Peptidase |
| SK-0403 | ||
| Anagliptin is a potent and selective DPP-4 inhibitor(IC50= 3.8 nM); > 10 fold less potent for DPP-8 and DPP-9. | ||
| M5952 | Saxagliptin hydrate | Dipeptidyl Peptidase |
| BMS-477118 hydrate, Onglyza hydrate, BMS 477118 hydrate, BMS477118 hydrate | ||
| Saxagliptin H2O is a selective and reversible DPP4 inhibitor with IC50 of 26 nM. | ||
| M5965 | Sitagliptin | Dipeptidyl Peptidase |
| MK0431 | ||
| Sitagliptin (MK 0431) is a potent inhibitor of DPP4 with IC50 of 19 nM in Caco-2 cell extracts. | ||
| M5994 | Teneligliptin hydrobromide hydrate | Dipeptidyl Peptidase |
| MP-513 hydrobromide hydrate | ||
| Teneligliptin (MP-513) hydrobromide hydrate is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor; competitively inhibited human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50 values of approximately 1 nM. | ||
| M5995 | Teneligliptin hydrobromide | Dipeptidyl Peptidase |
| MP-513 hydrobromide | ||
| Teneligliptin hydrobromide is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor; competitively inhibited human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50 values of approximately 1 nM. | ||
| M8882 | Trelagliptin succinate | Dipeptidyl Peptidase |
| SYR472 succinate | ||
| Trelagliptin(SYR-472) succinate is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D). | ||
| M10044 | Albiglutide | GLP Receptor |
| Albiglutide is a recombinant fusion protein consisting of two copies of a 30-amino-acid sequence of modified human GLP-1 (fragment 7-36), modified with a glycine substituted for the naturally occurring alanine at position 8 in order to augment resistance to DPP-4. | ||
| M11061 | Ladanein | Others |
| Ladanein is a phytochemicals inhibitor that is known to disrupt the interactions of core and other hepatitis C virus (HCV) proteins.Ladanein possesses free radicals DPPH and ABTS +.scavenging activity, it also displays moderate (20-40 microM) activities against K562, K562R (imatinib-resistant), and 697 human leukemia cell lines. | ||
| M14319 | Sitagliptin phosphate | Dipeptidyl Peptidase |
| MK-0431 phosphate | ||
| Sitagliptin phosphate (MK-0431 phosphate) is a potent inhibitor of DPP4 with an IC50 of 19 nM in Caco-2 cell extracts. | ||
| M14320 | Teneligliptin | Dipeptidyl Peptidase |
| MP-513 | ||
| Teneligliptin (MP-513) is a potent, orally available, competitive, and long-lasting DPP-4 inhibitor. Teneligliptin competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50s of approximately 1 nM. | ||
| M20841 | Gemigliptin | Dipeptidyl Peptidase |
| Zemiglo, LC15-0444 | ||
| Gemigliptin (Zemiglo, LC15-0444) is a potent, selective and long-acting dipeptidyl peptidase 4 (DPP 4) inhibitor with a Ki of 7.25 nM. Gemigliptin shows at least >23,000-fold selectivity for DPP-4 over various proteases and peptidases, including DPP-8, DPP-9, and fibroblast activation protein (FAP)-α. | ||
| M24648 | Begelomab | Others |
| SAND-26 | ||
| Begelomab (SAND-26) is a murine IgG2b monoclonal antibody against DPP-4/CD26. Begelomab can be used for the research of severe refractory idiopathic inflammatory myopathy. | ||
| M25319 | Anti-MERS-3A1 mAb | Anti-infection |
| MERS-3A1; MERS Antibody-3A1 | ||
| Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells. Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor. | ||
| M25320 | Anti-MERS-D12 mAb | Anti-infection |
| MERS-D12; MERS Antibody-D12 | ||
| Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding. | ||
| M27969 | Evogliptin | Dipeptidyl Peptidase |
| DA-1229 | ||
| Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation. | ||
| M27970 | Evogliptin tartrate | Dipeptidyl Peptidase |
| DA-1229 tartrate | ||
| Evogliptin (DA-1229) tartrate is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin tartrate also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin tartrate can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation. | ||
| M28160 | Fotagliptin | Dipeptidyl Peptidase |
| Fotagliptin is a Dipeptidyl Peptidase IV (DPP-4) inhibitor (IC50=2.27 nM). Fotagliptin displays great security in rat and dog. Fotagliptin can be used for Type 2 diabetes mellitus research. | ||
| M28341 | Fotagliptin benzoate | Dipeptidyl Peptidase |
| Fotagliptin benzoate is a Dipeptidyl Peptidase IV (DPP-4) inhibitor (IC50=2.27 nM). Fotagliptin benzoate displays great security in rat and dog. Fotagliptin benzoate can be used for Type 2 diabetes mellitus research. | ||
| M28460 | Lyoniresinol | Others |
| Lyoniresinol is a lignan isolated from the Tarenna attenuata with antioxidant activities. Lyoniresinol has radical scavenging activities against DPPH with an IC50 of 82.4 μM. | ||
| M28540 | Talabostat | Dipeptidyl Peptidase |
| Val-boroPro; PT100 | ||
| Talabostat (Val-boroPro; PT100) is an orally active and nonselective dipeptidyl peptidase IV (DPP-IV) inhibitor (IC50 < 4 nM; Ki = 0.18 nM) and the first clinical inhibitor of fibroblast activation protein (FAP) (IC50 = 560 nM), inhibits DPP8/9 (IC50 = 4/11 nM; Ki = 1.5/0.76 nM), quiescent cell proline dipeptidase (QPP) (IC50 = 310 nM), DPP2, and some other DASH family enzymes. Antineoplastic and hematopoiesis- stimulating activities. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
